Accepted Articles                   Back to the articles list | Back to browse issues page


XML Print


1- Clinical pharmacy department, Faculty of pharmacy, Deraya University, Minia, Egypt.
2- Internal Medicine and biomedical chemistry department, Egypt Ministry of Health and population. Minia, Egypt.
3- Neuropsychiatry department, Faculty of Medicine, Assiut University, Assiut, Egypt.
4- Pharmaceutics department, Faculty of Pharmacy, Minia University, Minia, Egypt.
Abstract:  
Background& Objectives: In this research, we investigated any possible effect of receiving Hyperbaric oxygen therapy (HBOT) or Risperidone on the autism core symptoms in children diagnosed as autism spectrum disorder (ASD).
Methods: A randomized, controlled clinical trial, in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, ages 5–8 years, divided into equal three groups, Group1 (G1): (N=60) received 40 sessions of (HBOT) within two months. Group2 (G2): (N=60) received Risperidone (0.25 mg daily for children under 20 kg; 0.5 mg daily for children equal to or over 20 kg) for six months. Group3 (G3): (N=60) control group received a placebo for six months. Assessment of their Childhood Autism Rating Scale (CARS) and Autism Treatment Evaluation Checklist (ATEC) scores was done at the beginning of the study (baseline) and after one year.
Results: The mean total CARS, total ATEC, and ATEC subscales scores were significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were in order (G1) then (G2) and finally (G3).
Interpretation & conclusions: There is a clear effect of using (HBOT) or Risperidone in treating the core symptoms of autism in children diagnosed as autism spectrum disorder. But using (HBOT) gives better results than using Risperidone therapy.
Keywords: Autism, ATEC, CARS, HBOT, Risperidone
Type of Study: Original | Subject: Clinical Neuroscience
Received: 2020/12/14 | Accepted: 2021/02/13

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb